References
- Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Affairs. 2006;25:313–324.
- Food and Drug Administration Amendments Act (FDAAA). Sec. 524. 2007.
- Gustavsen K. To improve pandemic preparedness, update the priority review voucher program. Health Affairs Blog. [2016 Mar 22; cited 2016 Aug 3]. Available from http://healthaffairs.org/blog/2016/03/22/to-improve-pandemic-preparedness-update-the-priority-review-voucher-program/.
- Karst KR. Congress continues spree of proposing alternative incentives for product development: the “CBRN Countermeasure PRV” (part 1). Hyman Phelps and McNamara FDA Law Blog. [ cited 2016 Aug 3]. Available from: http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/10/congress-continues-spree-of-proposing-alternative-incentives-for-product-development-the-cbrn-counte.html.
- Kesselheim AS, Maggs LR, Sarpatwari A. Experience with the priority review voucher program for drug development. JAMA. 2015;314:1687–1688.
- Kesselheim AS, Gagne JJ. Introduction to a supplement on innovative approaches to studying health outcomes in rare diseases. J Gen Intern Med. 2014;29(Suppl S3):709–711.
- McCaughan M. Priority review vouchers: FDA has “Concerns.” Informa Pharma Intelligence. 2015 [cited 2016 Aug 3]. Available from http://weinberggroup.com/fda-priority-review-program-thoughts/.
- Ridley DB, Dent J, Egerton-Warburton C. Efficacy of the priority review voucher program. JAMA. 2016;315(15):1659–1660.
- Aurora P, Romine M, Daniel G. Are priority review vouchers the answer to incentivize drug development? Not so fast. Health Affairs Blog. [2016 Jun 15; cited 2016 Aug 3]. Available from: http://healthaffairs.org/blog/2016/06/15/are-priority-review-vouchers-the-answer-to-incentivize-drug-development-not-so-fast/.
- Ravvin M. Incentivizing access and innovation for essential medicines: a survey of the problem and proposed solutions. Public Health Affairs. 2008;1(2):110–123.
- Government Accountability Office. Too early to gauge effectiveness of FDA’s pediatric voucher program. Report to Congressional Committees. [2016 Mar; cited 2016 Aug 3]. Available from: http://www.gao.gov/assets/680/675544.pdf.
- Ridley DB. The regulatory burden of the priority review voucher program. Health Affairs Blog. [2015 Oct 28; cited 2016 Aug 3]. Available from: http://healthaffairs.org/blog/2015/10/28/the-regulatory-burden-of-the-priority-review-voucher-program/.
- Ridley DB, Régnier SA. The commercial market for priority review vouchers. Health Affairs. 2016;35(5):776–783.
- Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development: an economically viable strategy for Biopharma R&D. Drug Discov Today. 2012;17(13–14):660–664.
- Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011;305(22):2320–2326.